FDA review of Moderna vaccine for teens to take longer


Moderna says the Food and Drug Administration's review of the company's COVID-19 vaccine for children ages 12 to 17 may not be finished before January because the agency is reviewing the vaccine's effect on myocarditis, which is heart muscle inflammation. Moderna also says it will delay its request for emergency use authorization for a smaller dose for children ages 6 to 11.

Full story:

AIChE SmartBrief

Chemical engineering news

Designed specifically for chemical engineers, AIChE SmartBrief is a FREE weekly e-mail newsletter. It helps chemical engineers stay informed on the business and technology developments affecting our profession.